Navigation Links
Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
Date:8/1/2008

SAN FRANCISCO, Aug. 1 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the BMO Capital Markets 2008 Focus on Healthcare Conference on Tuesday, August 5, at 11:15 a.m. Eastern Time at the Millennium Broadway Hotel in New York.

Dr. Hung will provide an overview of Medivation and its clinical development programs for Dimebon for Alzheimer's and Huntington's diseases and MDV3100 for prostate cancer.

A live audio webcast of the presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at http://www.medivation.com. A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial. For more information, please visit us at http://www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
2. Medivation Announces Senior Management Promotions
3. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
4. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
6. Cantel Medical Announces Management Succession at Crosstex Healthcare Disposables Subsidiary
7. Bioheart, Inc., Announces Letter of Intent to Acquire MEDICALGORITHMICS, Ltd.
8. Novavax Announces Closing of $18 Million Registered Direct Offering
9. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
10. Thermage, Inc. Announces Second Quarter 2008 Results Release Date and Conference Call
11. deCODE genetics Announces Webcast of Conference Call to Discuss Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... 3, 2016 New Jersey Health Foundation (NJHF) ... million for researchers in New Jersey ... that demonstrates exciting potential.   James ... the New Jersey Health Foundation Research Grant Program ... educational institutions— Princeton University, Rutgers University, Rowan University ...
(Date:2/3/2016)... ... February 03, 2016 , ... ProMIS Neurosciences is currently in ... to misfolded, propagating strains of Amyloid beta involved in Alzheimer’s disease. The Company ... , Following on from the first misfolded Amyloid beta target announced on Nov. ...
(Date:2/3/2016)... ... February 03, 2016 , ... Resilinc released ... and analyzes nearly 750 unique supply chain notifications and alerts generated by its ... Supply chain risk management practitioners subscribe to the EventWatch service to receive early ...
(Date:2/3/2016)...  Today, Symphony Technology Group (STG) announced the closing ... provider of primary research and analytics-based insight for biopharmaceutical ... a global information and technology services company serving the ... be integrated into IMS Health to form a foundation ... ...
Breaking Biology Technology:
(Date:2/2/2016)...   Parabon NanoLabs (Parabon) announced today ... Office and the Defense Forensics and Biometrics Agency ... company,s Snapshot Kinship Inference software for ... defense-related DNA forensics.  Although Snapshot is best known ... ancestry from DNA evidence), it also has the ...
(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of human interface ... 31, 2015. --> --> ... percent compared to the comparable quarter last year to $470.5 million. ... million, or $0.93 per diluted share. --> ... of fiscal 2016 grew 9 percent over the prior year period ...
(Date:1/22/2016)... 2016 http://www.researchandmarkets.com/research/p74whf/global_biometrics ... "Global Biometrics Market in Retail Sector ... --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has announced ... Market in Retail Sector 2016-2020" report ... Research and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has ...
Breaking Biology News(10 mins):